These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23883882)

  • 1. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011).
    Almuzaini T; Sammons H; Choonara I
    BMJ Open; 2013; 3(7):. PubMed ID: 23883882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013).
    Almuzaini T; Sammons H; Choonara I
    BMJ Open; 2014 Oct; 4(10):e006088. PubMed ID: 25361839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
    Machado Reis AT; Berardo BFR; Loureiro R
    PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems.
    Chabalenge B; Jere E; Nanyangwe N; Hikaambo C; Mudenda S; Banda M; Kalungia A; Matafwali S
    J Med Access; 2022; 6():27550834221141767. PubMed ID: 36601496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substandard, falsified and unregistered medicines in Latin America, 2017-2018.
    Rojas-Cortés R
    Rev Panam Salud Publica; 2020; 44():e125. PubMed ID: 33033498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
    Mori AT; Meena E; Kaale EA
    BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Epidemic of Substandard and Falsified Medications in Iraq: Evaluating the Effectiveness of National Pharmacovigilance Alerts to Community Pharmacies.
    Al-Jumaili AA; Younus MM; Saleh MZ
    Pharmaceut Med; 2021 May; 35(3):169-186. PubMed ID: 33864206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of drug recalls and quality of pharmaceutical products in Nepal.
    Neupane A; Bastakoti M; Tamang S; Giri B
    BMJ Open; 2022 Jul; 12(7):e053479. PubMed ID: 35788073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries.
    Rasheed H; Höllein L; Holzgrabe U
    Front Pharmacol; 2018; 9():995. PubMed ID: 30233373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counterfeit medicines in Peru: a retrospective review (1997-2014).
    Medina E; Bel E; Suñé JM
    BMJ Open; 2016 Apr; 6(4):e010387. PubMed ID: 27044580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
    Iloh GU; Akodu BA; Emeka EA; Obi IV
    West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substandard and Falsified Medicines in Myanmar.
    Sakuda M; Yoshida N; Takaoka T; Sanada T; Rahman MS; Tanimoto T; Zin T; Kimura K; Tsuboi H
    Pharmacy (Basel); 2020 Mar; 8(1):. PubMed ID: 32204459
    [No Abstract]   [Full Text] [Related]  

  • 16. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of drug safety alerts issued by the Spanish Medicines Agency.
    Montané E; Santesmases J
    Front Pharmacol; 2023; 14():1090707. PubMed ID: 36794271
    [No Abstract]   [Full Text] [Related]  

  • 20. Augmenting Product Defect Surveillance Through Web Crawling and Machine Learning in Singapore.
    Ang PS; Teo DCH; Dorajoo SR; Prem Kumar M; Chan YH; Choong CT; Phuah DST; Tan DHM; Tan FM; Huang H; Tan MSH; Ng MSY; Poh JWW
    Drug Saf; 2021 Sep; 44(9):939-948. PubMed ID: 34148223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.